Monoclonal antibodies in clinical development
| Name . | Target . | Trials phase . | Side effects . | Monotherapy . | Combination therapy . | Comments . |
|---|---|---|---|---|---|---|
| Elotuzumab | CS1 (SLAMF7) | 3 | Infusion reactions, lymphopenia, fatigue, pneumonia | No objective responses | With Rd: ORR: 84% with Vd: ORR 65% with PFS of 9.9 vs 6.8 months | FDA approved |
| Daratumumab | CD38 | 3 | Infusion reactions, cytopenias | ORR 35% at 16 mg/kg 10% CR | With Rd: ORR 93% with Pd: ORR 58% with Vd: ORR 83% | FDA approved |
| Isatuximab | CD38 | 1/2 | Fatigue, nausea, cytopenias, hyperglycemia, fever | ORR: At ≥10 mg/kg: 24% | With Rd: ORR 57% | |
| BT062 (indatuximab ravtansine) | CD138 | 1/2a | Nausea, fatigue, diarrhea, hypokalemia | Disease control (PR + SD) in 50% patients | With Rd: ORR 70-83% depending on dose and prior therapies | Conjugated with DM4 |
| Lorvotuzumab | CD56 | 1 | Cytopenias, peripheral neuropathy, fatigue, GI symptoms | Clinical benefit (≥stable disease): 41% including PR and and 4 mR | With Rd: ORR: 56.4% including 3% stringent complete remission, 28% VGPR and 26% PR | Conjugated with DM1 |
| Siltuximab (CNTO 328) | IL-6 | 1, 2 | Cytopenias, liver toxicity | No response | No advantage of combining with bortezomib | |
| Pembrolizumab | PD-1 | 1, 2 | Cytopenias, diarrhea | With Rd: ORR 50% with Pomalidomide:ORR 50% |
| Name . | Target . | Trials phase . | Side effects . | Monotherapy . | Combination therapy . | Comments . |
|---|---|---|---|---|---|---|
| Elotuzumab | CS1 (SLAMF7) | 3 | Infusion reactions, lymphopenia, fatigue, pneumonia | No objective responses | With Rd: ORR: 84% with Vd: ORR 65% with PFS of 9.9 vs 6.8 months | FDA approved |
| Daratumumab | CD38 | 3 | Infusion reactions, cytopenias | ORR 35% at 16 mg/kg 10% CR | With Rd: ORR 93% with Pd: ORR 58% with Vd: ORR 83% | FDA approved |
| Isatuximab | CD38 | 1/2 | Fatigue, nausea, cytopenias, hyperglycemia, fever | ORR: At ≥10 mg/kg: 24% | With Rd: ORR 57% | |
| BT062 (indatuximab ravtansine) | CD138 | 1/2a | Nausea, fatigue, diarrhea, hypokalemia | Disease control (PR + SD) in 50% patients | With Rd: ORR 70-83% depending on dose and prior therapies | Conjugated with DM4 |
| Lorvotuzumab | CD56 | 1 | Cytopenias, peripheral neuropathy, fatigue, GI symptoms | Clinical benefit (≥stable disease): 41% including PR and and 4 mR | With Rd: ORR: 56.4% including 3% stringent complete remission, 28% VGPR and 26% PR | Conjugated with DM1 |
| Siltuximab (CNTO 328) | IL-6 | 1, 2 | Cytopenias, liver toxicity | No response | No advantage of combining with bortezomib | |
| Pembrolizumab | PD-1 | 1, 2 | Cytopenias, diarrhea | With Rd: ORR 50% with Pomalidomide:ORR 50% |